



PUTTING THE COST INTO COST-EFFECTIVENESS

Wednesday, 17 October 2018, 10.00 am-3.00 pm
Front + Centre, Ctr Tory & Tennyson St, Wellington

SPEAKERS

Andrew Wooding has been involved in clinical coding since 1986. In that time he has worked for the Otago, Capital Coast and Auckland District Health Boards and, for the Ministry of Health. He is currently the Clinical Coding Training and Quality Coordinator at Auckland DHB, where he has been working since 2001. Andrew is well-known throughout New Zealand clinical coding departments, having been involved in several national training initiatives. He represents Auckland DHB on the New Zealand Coding Authority and has been involved in finding solutions to classification problems and recommending updates to the classifications.

Richard Milne is a private consultant in health technology assessment and Associate Professor in the School of Pharmacy at the University of Auckland. Over 20+ years he has developed prospective economic models of novel interventions including pharmaceuticals, vaccines, medical devices and clinical programmes; also, real world evidence on the impact of recently funded interventions in NZ. Richard was a founding member of ISPOR and first President of ISPOR NZ

Matt Boyd is a private research contractor and freelance academic, who has conducted analyses for the former National Health Committee, Ministry of Health, Health Quality and Safety Commission, and the Burden of Disease Epidemiology, Equity and Cost-Effectiveness (BODE3) Programme.

PROGRAMME

- 9.30 am Venue open, refreshments available
- 10.00 am **Welcome:** James Harris, President, ISPOR (NZ)
- 10.10 am **But where does the data come from?**
Andrew Wooding
The process of turning clinical documentation into data that are usable for research, costing, epidemiology, and monitoring quality of care is not well understood by end-users of the data. We will explore some of the limitations of the data in the NZ context before turning our attention to the riches to be found in the National Minimum DataSet (NMDS). Along the way we will explain the Casemix model as it is used in the NZ health environment.
- 10.50 am **Preparing for the scavenger hunter: the epidemiological base for a cost of illness study**
Richard Milne
Bottom-up costing studies require a range of patient-level epidemiological evidence. Richard will talk about obtaining real world evidence from multiple NZ datasets ('Big Data') to inform a recent study on the national cost of a blood cancer.
- 11.30 pm **The scavenger hunter: one analyst's experience in obtaining cost-of-illness data in New Zealand**
Matt Boyd
Matt will describe his experience in obtaining cost data for economic evaluations, cost-of-illness studies, or for other analytical purposes in New Zealand. The talk will cover diverse sources of data, quality of data, useful practice points and pitfalls.



PUTTING THE COST INTO COST-EFFECTIVENESS

SPEAKERS

Anita Fitzgerald is a Scientific Research Consultant for the Northern Region Clinical Practice Committee (NZ) and York Health Economics Consortium (UK). Anita conducts a wide range of clinical- and cost-effectiveness reviews, meta-analyses and hospital-based health technology assessments including drug reviews, device reviews, screening reviews and public health reviews.

Tal Sharrock is a health economist at PHARMAC and will be presenting the findings of her public health master's thesis.

PROGRAMME CONTINUED

12.10 pm **Strengthening decision making using local data: a case study**
Anita Fitzgerald
Medical technologies continue to become available at a rate that exceeds the publication of comparative data on their effectiveness and for which the availability of local data and costs are often limited. Decision making is difficult in this context. This case study provides one method of approaching these issues and demonstrates that even in the absence of definitive published data and where local data is lacking, HTA units can take steps to strengthen and justify decisions made.

12.25 pm **LUNCH**

1.15 pm **Cost-effectiveness of combination vs monotherapy to prevent cardiovascular disease (CVD)**
Tal Sharrock
Tal's thesis looked at the cost-effectiveness of a two-agent, multi-risk factor, fixed-dose combination treatment compared to equivalent monotherapies as a primary preventive measure for CVD in NZ. Combining two or more pharmaceuticals into a single fixed-dose combination is one identified method to address evident issues of non-adherence to CVD pharmaceutical regimens and ensure the intended positive impact of the pharmaceuticals can be realised. Achieving better risk factor control has the potential to improve the health of individuals and produce health system savings through a reduction in CVD events.



PUTTING THE COST INTO COST-EFFECTIVENESS

SPEAKERS

Dr Matt Glasgow is a medically-trained doctor with a background in health informatics and clinical decision support system design, currently undertaking PhD research at the Liggins Institute, University of Auckland. Working within the LifePATH group, Matt is performing economic analyses related to the management of neonatal hypoglycaemia, a common metabolic condition that affects up to 50% of newborn babies in some at-risk groups, and which can have severe consequences like epilepsy, cerebral palsy, or learning difficulties that affect the infant for the rest of their life.

Monica Garrett is a senior medical student from Auckland University. She's currently working towards her Bachelor of Medical Science with Honours degree. She will return for her final year of medical school in 2019, based at Rotorua Hospital.

James Harris, Manager Health Economics, PHARMAC.

SPONSORED BY ISPOR NZ
ispornewzealand@gmail.com

PROGRAMME CONTINUED

- 1.30 pm **Economic analyses of neonatal hypoglycaemia**
Matt Glasgow
Matt's PhD research is in the form of a series of analyses examining the long-term outcomes and social and economic costs of neonatal hypoglycaemia (NH), high blood sugars that can affect newborn babies shortly after birth. By determining the potential costs and cost savings of using dextrose gel to prevent NH in newborn babies at risk, the hope is to reduce the impact it has on babies as they grow up, and their families.
- 1.45 pm **Bariatric surgery in NZ over the last 10 years**
Monica Garrett
Monica's presentation will focus on bariatric surgery in NZ. Her talk will describe the provision of bariatric surgery, nationwide, over the last decade. Post-surgical changes in the use of medications targeting cardiovascular disease risk management will also be discussed.
- 2.00 pm **PHARMAC's cost resource manual – an update**
James Harris
PHARMAC publishes a standardised list of prices and costs that are useful for health technology assessments across the New Zealand health sector. James will introduce the manual and its most recent update, then discuss some of the issues in choosing appropriate prices for analyses of technologies and health services.
- 2.40 pm **AFTERNOON TEA**



REGISTRATION FORM

To register for the meeting please fill in the registration form below and email to:

ispornewzealand@gmail.com

Name: _____

Company or Institution: _____

Email address: _____

Phone contact: _____

- Cost:
- \$100** non-member
 - \$50** ISPOR (NZ) member / Student / ISPOR (International) member
 - \$125** for annual ISPOR (NZ) membership and meeting attendance
 - \$100** for ISPOR (NZ) membership and meeting attendance if an ISPOR int. member

Require invoice: Yes No

Payment by electronic credit to: ISPOR NZ Chapter, Acc no. 03-1702-0365754-00

Please put your name as a reference when making payment.

Signature: _____

- I am happy for my details to be retained on file for further contact
- Please do not retain a record of my contact details